Zhejiang East Asia Pharmaceutical Co., Ltd.

SHSE:605177 Stock Report

Market Cap: CN¥2.5b

Zhejiang East Asia Pharmaceutical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Cheng Chi

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership6.9%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

May 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Apr 23
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)

Feb 28
Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)

CEO

Cheng Chi (40 yo)

no data

Tenure

CN¥1,109,200

Compensation

Mr. Cheng Chi serves as Director and General Manager at Zhejiang East Asia Pharmaceutical Co., Ltd. and served as its Deputy Manager.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.